WordNet
- a cellular structure that is postulated to exist in order to mediate between a chemical agent that acts on nervous tissue and the physiological response
- the 13th letter of the Roman alphabet (同)m
- the imperial dynasty of China from 1368 to 1644 (同)Ming dynasty
- a form of address for a woman (同)Ms.
PrepTutorEJDIC
- =sense organ / 受信装置
- Mach number / mark[s] / Monsieur
- (中国の)明,明朝(1368‐1644)
- mendeleviumの化学記号
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2017/10/27 04:39:16」(JST)
[Wiki en表示]
OSMR |
|
Identifiers |
Aliases |
OSMR, OSMRB, PLCA1, IL-31R-beta, IL-31RB, oncostatin M receptor |
External IDs |
OMIM: 601743 MGI: 1330819 HomoloGene: 2972 GeneCards: OSMR |
Gene location (Human) |
|
Chr. |
Chromosome 5 (human)[1] |
|
Band |
5p13.1 |
Start |
38,845,858 bp[1] |
End |
38,945,596 bp[1] |
|
Gene location (Mouse) |
|
Chr. |
Chromosome 15 (mouse)[2] |
|
Band |
15 A1|15 3.3 cM |
Start |
6,813,577 bp[2] |
End |
6,874,969 bp[2] |
|
Gene ontology |
Molecular function |
• cytokine receptor activity
• oncostatin-M receptor activity
• growth factor binding
|
Cellular component |
• integral component of membrane
• oncostatin-M receptor complex
• plasma membrane
• apical plasma membrane
• membrane
|
Biological process |
• positive regulation of acute inflammatory response
• response to cytokine
• oncostatin-M-mediated signaling pathway
• positive regulation of cell proliferation
|
Sources:Amigo / QuickGO |
|
Orthologs |
Species |
Human |
Mouse |
Entrez |
|
|
Ensembl |
|
|
UniProt |
|
|
RefSeq (mRNA) |
NM_001168355
NM_003999
NM_001323504
NM_001323505
NM_001323506
|
NM_001323507
|
|
|
RefSeq (protein) |
NP_001161827
NP_001310433
NP_001310434
NP_001310435
NP_001310436
|
NP_003990
|
|
|
Location (UCSC) |
Chr 5: 38.85 – 38.95 Mb |
Chr 5: 6.81 – 6.87 Mb |
PubMed search |
[3] |
[4] |
Wikidata |
View/Edit Human |
View/Edit Mouse |
|
Oncostatin-M specific receptor subunit beta also known as the oncostatin M receptor, is one of the receptor proteins for oncostatin M, that in humans is encoded by the OSMR gene.[5][6]
OSMR is a member of the type I cytokine receptor family. This protein heterodimerizes with interleukin 6 signal transducer to form the type II oncostatin M receptor and with interleukin 31 receptor A to form the interleukin 31 receptor, and thus transduces oncostatin M and interleukin 31 induced signaling events.[5]
Clinical significance
The oncostatin M receptor is associated with primary cutaneous amyloidosis.[7]
References
- ^ a b c GRCh38: Ensembl release 89: ENSG00000145623 - Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000022146 - Ensembl, May 2017
- ^ "Human PubMed Reference:".
- ^ "Mouse PubMed Reference:".
- ^ a b "Entrez Gene: oncostatin M receptor".
- ^ Mosley B, De Imus C, Friend D, Boiani N, Thoma B, Park LS, Cosman D (December 1996). "Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation". J. Biol. Chem. 271 (51): 32635–43. PMID 8999038. doi:10.1074/jbc.271.51.32635.
- ^ Arita K, South AP, Hans-Filho G, et al. (January 2008). "Oncostatin M Receptor-β Mutations Underlie Familial Primary Localized Cutaneous Amyloidosis". Am. J. Hum. Genet. 82 (1): 73–80. PMC 2253984 . PMID 18179886. doi:10.1016/j.ajhg.2007.09.002.
External links
- Oncostatin M Receptor at the US National Library of Medicine Medical Subject Headings (MeSH)
This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Cytokine receptors
|
Chemokine receptor
(GPCRs) |
CC |
- CCR1 / CCRL1
- CCR2
- CCRL2
- CCR3
- CCR4
- CCR5
- CCR6
- CCR7
- CCR8
- CCR9
- CCR10
|
CXC |
- IL-8
- CXCR3
- CXCR4
- CXCR5
- CXCR6
- CXCR7
|
Other |
|
|
TNF receptor |
1-10 |
- TNFR1 (TNFRSF1A)
- TNFR2 (TNFRSF1B)
- LTBR (TNFRSF3)
- CD134 (TNFRSF4)
- CD40 (TNFRSF5)
- Fas receptor (TNFRSF6)
- DcR3 (TNFRSF6B)
- CD27 (TNFRSF7)
- CD30 (TNFRSF8)
- CD137 (TNFRSF9)
|
11-20 |
- DR4 (TNFRSF10A)
- DR5 (TNFRSF10B)
- DcR1 (TNFRSF10C)
- DcR2 (TNFRSF10D)
- RANK (TNFRSF11A)
- Osteoprotegerin (TNFRSF11B)
- TweakR (TNFRSF12A)
- TACI (TNFRSF13B)
- BAFFR (TNFRSF13C)
- HVEM (TNFRSF14)
- NGFR (TNFRSF16)
- BCMA (TNFRSF17)
- GITR (TNFRSF18)
- TAJ/TROY (TNFRSF19)
|
21-27 |
- DR6 (TNFRSF21)
- DR3 (TNFRSF25)
- EDA2R (TNFRSF27)
|
|
JAK-STAT |
Type I |
γ-chain |
- Interleukin receptors
- IL2R / IL2RA/IL2RB / IL15R
- IL4R / IL13R / IL13RA1 / IL13RA2
- IL7R / IL7RA
- IL9R
- IL21R
|
β-chain |
- Interleukin receptors
- IL3R / IL3RA
- IL5R / IL5RA
- GM-CSF
|
gp130 |
- Interleukin receptors
- IL6RA
- 11/IL11RA
- 27/IL27RA
- OSMR
- LIFR
- CNTFR
|
IL12RB1 |
- Interleukin receptors
- IL12R/IL12RB1/IL12RB2
- IL23R23
|
Other |
- hormone receptor: GH
- prolactin
|
|
Type II |
- Interleukin receptors
- IL10R / IL10RA / IL10RB / IL22R / IL22RA1 / IL22RA2
- IL20R / IL20RA / IL20RB
- IL28R
- Interferon receptors
- -α/β / IFNAR1/IFNAR2
- -γ/IFNGR1 / IFNGR2
|
|
Ig superfamily |
- CSF1
- KIT
- IL1
- IL18R / IL18R1
|
IL 17 family |
- IL17
- IL17RA
- IL17RB
- IL17RC
- IL17RD
- IL17RE
|
S/T |
|
Cytokine receptor modulators
|
Chemokine |
|
CSF |
Erythropoietin |
- Agonists: ARA-290
- Asialo erythropoietin
- Carbamylated erythropoietin
- CNTO-530
- Darbepoetin alfa
- Epoetin alfa
- Epoetin beta
- Epoetin delta
- Epoetin epsilon
- Epoetin gamma
- Epoetin kappa
- Epoetin omega
- Epoetin theta
- Epoetin zeta
- Erythropoietin (EPO)
- Erythropoietin-Fc
- Methoxy polyethylene glycol-epoetin beta (CERA/Mircera)
- Peginesatide
- Pegol sihematide (EPO-018B)
|
G-CSF (CSF3) |
- Agonists: Filgrastim
- Granulocyte colony-stimulating factor
- Lenograstim
- Leridistim
- Lipegfilgrastim
- Nartograstim
- Pegfilgrastim
- Pegnartograstim
|
GM-CSF (CSF2) |
- Agonists: Ecogramostim
- Granulocyte macrophage colony-stimulating factor
- Milodistim
- Molgramostim
- Regramostim
- Sargramostim
- Antibodies: Mavrilimumab
- MOR103
- Namilumab
|
M-CSF (CSF1) |
- Agonists: Cilmostim
- Interleukin-34
- Lanimostim
- Macrophage colony-stimulating factor
- Mirimostim
- Kinase inhibitors: Agerafenib
|
SCF (c-Kit) |
|
Thrombopoietin |
- Agonists: Eltrombopag
- Pegacaristim
- Promegapoietin
- Romiplostim
- Thrombopoietin (THPO, MGDF)
|
|
Interferon |
IFNAR (α/β, I) |
- Agonists: Albinterferon
- Interferon alpha (interferon alfa, IFN-α)
- Interferon alfa (IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA21)
- Interferon alfa 2a
- Interferon alfa 2b
- Interferon alfa n1
- Interferon alfacon-1
- Interferon alpha-n3
- Interferon beta (IFN-β) (IFNB1, IFNB3)
- Interferon beta 1a
- Interferon beta 1b
- Interferon kappa (IFN-ε/κ/τ/ζ, IFNK)
- Interferon omega (IFN-ω, IFNW1)
- Peginterferon alfa-2a
- Peginterferon alfa-2b
- Antibodies: Anifrolumab
- Faralimomab
- MEDI-545
- Rontalizumab
- Sifalimumab
- Decoy receptors: Bifarcept
|
IFNGR (γ, II) |
- Agonists: Interferon gamma (IFN-γ)
- Interferon gamma 1b
- Antibodies: Emapalumab
- Fontolizumab
|
IFNLR (λ, III) |
- See IL-28R (IFNLR) here instead.
|
|
Interleukin |
|
TGFβ |
|
TNF |
|
Others |
JAK
(inhibitors) |
JAK1 |
- Baricitinib
- Filgotinib
- Momelotinib
- Oclacitinib
- Ruxolitinib
- Tofacitinib (tasocitinib, CP-690550)
- Upadacitinib
|
JAK2 |
- AG-490
- Atiprimod
- AZD-1480
- Baricitinib
- CHZ868
- Cucurbitacin I (elatericin B, JSI-124)
- CYT387
- Lestaurtinib
- NSC-7908
- NSC-33994
- Pacritinib
- Ruxolitinib
- SD-1008
- Tofacitinib (tasocitinib, CP-690550)
|
JAK3 |
- AG-490
- Cercosporamide
- TCS-21311
- Tofacitinib (tasocitinib, CP-690550)
- WHI-P 154
- ZM-39923
- ZM-449829
|
|
Others |
- Additional cytokines: Cardiotrophin 1 (CT-1)
- FMS-like tyrosine kinase 3 ligand (FLT3L)
- Leukemia/leukocyte inhibitory factor (LIF)
- Oncostatin M (OSM)
- Thymic stromal lymphopoietin (TSLP)
- Additional cytokine receptor modulators: Emfilermin
- Lestaurtinib
- Midostaurin
- Quizartinib
- Sorafenib
- Sunitinib
|
|
- See also
- Receptor/signaling modulators
- Signaling peptide/protein receptor modulators
- Growth factor receptor modulators
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. アミロイドーシスの皮膚症状cutaneous manifestations of amyloidosis [show details]
…detected in families in Japan, China, Taiwan, and Brazil. Mutations in the oncostatin M receptor beta (OSMRB) and interleukin-31 receptor A (IL31RA) genes have been found in affected families . Familial cases …
- 2. インスリン受容体の構造および機能structure and function of the insulin receptor [show details]
… its receptor protein have been the subject of intense investigation . The insulin receptor gene maps to human chromosome 19 and spans more than 150 kilobases (kb) . The 22 exons of the receptor gene …
- 3. T細胞受容体の遺伝学t cell receptor genetics [show details]
…determined. There are two types of T cell receptors (TCRs). The majority (95 percent or more) of peripheral blood T cells bear a heterodimeric receptor made of two chains called alpha and beta, also …
- 4. β-2アドレナリン受容体機能不全および喘息の多型性beta 2 adrenergic receptor dysfunction and polymorphism in asthma [show details]
… at the beta-2 adrenergic receptor did not begin until the late 1980s. The mechanisms of signal transduction from this receptor and the potential role of beta-2 adrenergic receptor dysfunction in the pathogenesis …
- 5. アンギオテンシン変換酵素阻害剤とアンギオテンシン受容体拮抗剤との相違differences between angiotensin converting enzyme inhibitors and receptor blockers [show details]
…ACE inhibitors and angiotensin II receptor antagonists: the receptors that are affected and the effect on kinins Angiotensin II can activate both AT1 and AT2 receptors. As a result, inhibition of angiotensin …
English Journal
- Clinical and genetic features of Chinese patients with lichen and macular primary localized cutaneous amyloidosis.
- Lu P, Wu FF, Rong ZL, Fang C, Deng CC, Bin LH, Yang B.
- Clinical and experimental dermatology. 2019 Jun;44(4)e110-e117.
- Primary localized cutaneous amyloidosis (PLCA) is a chronic pruritic skin disorder. The genetic basis of familial (f)PLCA involves mutations in the oncostatin M receptor (OSMR) and interleukin-31 receptor A (IL31RA) genes, but the disease pathophysiology is not fully understood. To investigate the O
- PMID 30734345
- Primary Localized Cutaneous Amyloidosis Affecting Female Individuals of a Pakistani Pedigree.
- Bhoyrul B, Ng A, Laws PM, Mathew B, Shanmugam S.
- The American Journal of dermatopathology. 2019 May;41(5)382-385.
- Primary localized cutaneous amyloidosis is a group of rare conditions where amyloid deposition is limited to the skin without systemic manifestations. Most cases are sporadic; however, mutations in the oncostatin M receptor (OSMR) and interleukin-31 receptor A (IL31RA) genes can cause a familial for
- PMID 30308545
- Inhibition of JAK1/2 Tyrosine Kinases Reduces Neurogenic Heterotopic Ossification After Spinal Cord Injury.
- Alexander KA, Tseng HW, Fleming W, Jose B, Salga M, Kulina I, Millard SM, Pettit AR, Genêt F, Levesque JP.
- Frontiers in immunology. 2019 ;10()377.
- Neurogenic heterotopic ossifications (NHO) are very incapacitating complications of traumatic brain and spinal cord injuries (SCI) which manifest as abnormal formation of bone tissue in periarticular muscles. NHO are debilitating as they cause pain, partial or total joint ankylosis and vascular and
- PMID 30899259
Japanese Journal
- Oncostatin M receptor, positively regulated by SP1, promotes gastric cancer growth and metastasis upon treatment with Oncostatin M
- Yu Zhenjia,Li Zhen,Wang Chenchen,Pan Tao,Chang Xinyu,Wang Xiaofeng,Zhou Quan,Wu Xiongyan,Li Jianfang,Zhang Jinping,Liu Bingya,Zhu Zhenggang,Su Liping
- Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 22(5), 955-966, 2019
- NAID 40021979043
- Simvastatin inhibits CD44 fragmentation in chondrocytes
- Terabe Kenya,Takahashi Nobunori,Takemoto Toki,Knudson Warren,Ishiguro Naoki,Kojima Toshihisa
- Archives of Biochemistry and Biophysics (604), 1-10, 2016-08-25
- … In human osteoarthritic chondrocytes, the hyaluronan receptor CD44 undergoes proteolytic cleavage at the cell surface. … Treatment with IL-1β + Oncostatin M resulted in a substantial increase in CD44 fragmentation in each of the three chondrocyte models. …
- NAID 120005868236
- Virus and Host Events in Squamous Carcinogenesis
- Coleman Nicholas
- The Keio Journal of Medicine 65(4), 78-78, 2016
- … The oncostatin-M receptor (OSMR) in metastasis</p><p>The cell-surface oncostatin-M receptor (OSMR) has emerged as an exciting therapeutic target in SCCs. …
- NAID 130007314619
Related Links
- This gene encodes a member of the type I cytokine receptor family. The encoded protein heterodimerizes with interleukin 6 signal transducer to form the type II oncostatin M receptor and with interleukin 31 receptor A to ...
- The mature IL-31 protein is the result of 164-amino acids precursor processing. This cytokine signals through a receptor complex composed of two subunits, IL-31 receptor A (IL-31RA) and oncostatin M receptor (OSMR), which are
- BACKGROUND: Oncostatin M receptor (OSMR) is a member of the interleukin 6 (IL-6) receptor family that transduces signaling events of Oncostatin M (OSM). OSM-OSMR signaling plays a key role in inflammation and cancer
★リンクテーブル★
[★]
- 英
- oncostatin M receptor
- 関
- オンコスタチンMレセプター
[★]
- 英
- oncostatin M receptor
- 関
- オンコスタチンM受容体
[★]
[★]
II型オンコスタチンM受容体
[★]
メンデレビウム mendelevium
[★]
メチオニン methionine